Nova Eye Medical Limited

ASX:EYE Rapport sur les actions

Capitalisation boursière : AU$55.0m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Nova Eye Medical Résultats passés

Passé contrôle des critères 0/6

Nova Eye Medical's earnings have been declining at an average annual rate of -16.8%, while the Medical Equipment industry saw earnings growing at 5.6% annually. Revenues have been declining at an average rate of 17.3% per year.

Informations clés

-16.8%

Taux de croissance des bénéfices

-13.7%

Taux de croissance du BPA

Medical Equipment Croissance de l'industrie5.8%
Taux de croissance des recettes-17.3%
Rendement des fonds propres-84.1%
Marge nette-76.2%
Dernière mise à jour des bénéfices31 Dec 2023

Mises à jour récentes des performances passées

Recent updates

Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)

Aug 06
Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)

Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward

Apr 18
Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward

Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?

Mar 26
Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?

News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Jan 19
News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

Dec 27
Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate

Sep 03
We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate

Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified

Apr 17
Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified

Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?

Dec 16
Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?

We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully

Aug 27
We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully

Ventilation des recettes et des dépenses

Comment Nova Eye Medical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

ASX:EYE Recettes, dépenses et bénéfices (AUD Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Dec 2319-14220
30 Sep 2318-15220
30 Jun 2317-15220
31 Mar 2316-13210
31 Dec 2215-11210
30 Sep 2214-9190
30 Jun 2213-7170
31 Mar 2213-7160
31 Dec 2113-6150
30 Sep 2113-5140
30 Jun 2113-4130
31 Dec 2012-9120
30 Sep 2013-10130
30 Jun 2013-10140
31 Dec 1916-6160
30 Sep 1916-6170
30 Jun 1916-7180
31 Mar 1948-7341
31 Dec 1849-6341
30 Sep 1864-6371
30 Jun 1879-5411
31 Mar 1877-5361
31 Dec 1775-5321
30 Sep 1773-3311
30 Jun 1772-1291
31 Mar 17721281
31 Dec 16733271
30 Sep 16733261
30 Jun 16733261
31 Mar 16703241
31 Dec 15672221
30 Sep 15652221
30 Jun 15632211
31 Mar 15611201
31 Dec 14591191
30 Sep 14571181
30 Jun 14541171
31 Mar 14510161
31 Dec 1347-1151
30 Sep 1345-1151

Des revenus de qualité: EYE is currently unprofitable.

Augmentation de la marge bénéficiaire: EYE is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: EYE is unprofitable, and losses have increased over the past 5 years at a rate of 16.8% per year.

Accélération de la croissance: Unable to compare EYE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: EYE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Rendement des fonds propres

ROE élevé: EYE has a negative Return on Equity (-84.09%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé